News

The Head of Quality Assurance & Qualified Person at 3P Biopharmaceuticals, Susana Santesteban, has attended ‘Lidera en femenino-STEM’, a course that aims to help promote the career advancement of STEM women.

3P Biopharmaceuticals and Buzzard Pharmaceuticals have entered into a partnership agreement for cGMP manufacturing of the potent IL-1 inhibitor Isunakinra, a recombinant protein for cancer indications.

Ion Arocena, CEO of AseBio, has delivered a speech at an event organised as part of the agreement that 3P Biopharmaceuticals has signed with the School of Pharmacy and Nutrition of the University of Navarra to promote training in Biotechnology

This collaboration agreement aims to reinforce the figure of the pharmacist and other health science professionals as expert scientists, to collaborate with the academic world in developing industrial knowledge and drug manufacturing, and to promote their training.

Biotech companies Invizius and 3P Biopharmaceuticals collaborate on an innovative technology for patients undergoing hemodialysis and suffering from cardiovascular disease

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has signed a manufacturing agreement withSpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics incorporates a new member to the management team and appoints Iker Portugal as Chief Financial Officer.

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, together with Toleranzia, a Swedish Biotech company, have initiated a collaboration on innovative treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG).

3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.